HUYABIO International Reveals HBI-8000 and Nivolumab Combination Cuts Disease Progression Risk by 27% in Advanced Melanoma Phase 3 Trial
Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27%Median progression-free survival was 11.7 months with HBI-8000 plus nivolumab compared…